

Medtech player Alcon expands manufacturing facility in Singapore

27 June 2025 | News

Expansion expected to create new high-value jobs in manufacturing, quality control, and distribution management



Alcon, the global leader in eye care, has announced the official opening of its expanded state-of-the-art manufacturing and logistics facility in Tuas Biomedical Park, Singapore.

The event was held in conjunction with the 20th anniversary of Alcon's operations in Singapore, a meaningful milestone that highlights two decades of innovation, high-precision manufacturing, and a commitment to improving lives through better vision. Alcon marked the occasion with a ceremony attended by Low Yen Ling, Senior Minister of State for the Ministry of Trade and Industry.

The completed Tuas facility, one of Alcon's largest high-tech manufacturing facilities, is equipped with advanced automation, smart manufacturing systems, and industry 4.0 capabilities to meet the growing global demand for Alcon's innovative contact lenses portfolio.

It will support the global production of Alcon's flagship PRECISION1® contact lenses, which feature proprietary SMARTSURFACE® Technology, setting new standards in comfort and clarity for millions of lens wearers worldwide.

Since establishing its first manufacturing site in Singapore in 2005, Alcon has consistently invested in the country's talent, technology, and infrastructure, committing more than \$600 million in investment to date. The latest completed expansion is expected to create new high-value job opportunities, including specialized roles in production operations, quality control, and distribution management.

The new Tuas facility is designed with both operational and environmental performance in mind. Featuring high levels of automation, integrated digital systems, and sustainability-focused design, it delivers energy and water savings, waste reduction, and improved throughput. Alcon's Tuas facility achieved zero waste to landfill, and offers scalable production capabilities to meet evolving global needs.

In 2024, Alcon invested \$876 million in research and development globally, secured 37 new product approvals in major markets, initiated 57 clinical trials, and had over 70 pipeline products under development.

The Tuas facility will support Singapore's ambition to grow its MedTech workforce, which comprises over 400 companies and employs more than 16,000 people as of 2024. Through partnerships with local educational institutions and workforce

development programs such as the Talent Advancement Programme and the Alcon Education Assistance Programme, Alcon aims to continue nurturing capabilities in precision engineering, biomedical sciences, and AI-driven automation, contributing to the expansion and advancement of the country's MedTech sector.